Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has announced that its pilot multiple sclerosis (MS) imaging study, conducted in collaboration with Massachusetts General Hospital, has reached the halfway point in patient enrollment. Preliminary PET imaging data from the study show encouraging signals in acute MS lesions, suggesting that the novel imaging technique may offer a more precise method for distinguishing between demyelinated nerve fibers that could still recover and those that have suffered permanent damage. This distinction is crucial for accurately measuring myelin loss and repair, which could transform how MS progression is monitored.
The study's relevance extends to Lucid-MS, Quantum BioPharma's investigational compound designed to inhibit demyelination by targeting the enzyme PAD2, which is implicated in myelin degradation. The combination of a more precise imaging tool and a drug candidate aimed at addressing the underlying cause of MS presents a compelling approach. Reaching the enrollment midpoint with promising early data suggests the science is holding up under real clinical conditions, according to a recent article. The full article can be accessed at https://nnw.fm/fsDHa.
Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is advancing Lucid-MS, a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models. Beyond MS, Quantum BioPharma has also developed unbuzzd, an over-the-counter product, and spun off its OTC version to Unbuzzd Wellness Inc. (UWI). The company retains a 19.84% ownership stake in UWI as of March 31, 2026, and is entitled to royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains full rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
The latest news and updates regarding QNTM are available in the company's newsroom at https://ibn.fm/QNTM. This development marks a significant milestone in the ongoing efforts to improve MS diagnosis and treatment, potentially leading to better outcomes for patients who currently face limited options for monitoring disease progression and response to therapy.
